nvg-291
Peptideexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 6, 2021 (NCT05308953)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- PTPsigma-(Brain)INHIBITOR
PTPsigma inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05965700 | Phase 1/Phase 2 (Phase 2) | Aug 8, 2023 | NervGen Pharma |
| NCT05308953 | Phase 1 | May 6, 2021 | NervGen Pharma, Union Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NervGen Pharma | For profit | 2 | 2 | 2 | 2021 |
| Union Therapeutics | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1